

SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, announced that the company will present at Redeye's Autoimmune and Inflammatory Diseases event in Stockholm on November 19th at 14:05 CET.

SynAct's Chief Business Officer Mads Bjerregaard will present the latest on lead compound resomelagon, a potential first-in-class, non-suppressive immune system modulator, and the potential use in treatments for rheumatoid arthritis and acute inflammation due to viral infections.

"I'm excited to join peers from Swedish biotech at the Redeye event presenting our innovations in the field of immunology," said Mads Bjerregaard, CSO at SynAct. "We believe that resomelagon is a novel approach to help patients overcome inflammatory disorder and we are excited to share our updates with investors in this important field of medicine."

To view the presentation online use the following link:

<https://www.redeye.se/events/1112314/redeye-theme-autoimmune-and-inflammatory-diseases-2>

For further information, please contact:

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: + 45 2844 7567

E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: <https://synactpharma.com/>.

Attachments

[SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th](#)